Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESSO 43 | ESSO43: collaboration, inclusiveness, and advances in multidisciplinary cancer care

Mariela Vasileva-Slaveva • 4 Oct 2024
ESSO 43
Breast Cancer

Mariela Vasileva-Slaveva, MD, PhD, University Hospital Alexandrovska, Sofia, Bulgaria, highlights the two key themes from the conference: the collaborative effort to cure cancer and the importance of inclusiveness. She discusses the need for a multidisciplinary approach to cancer treatment, the growing role of patient-reported outcomes, and advances in treatment techniques such as ultrasound and ICG to guide decision-making. This interview took place at the ESSO 43 congress in Antwerp, Belgium.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Mariela Vasileva-Slaveva

Breast conservation benefits: oncoplastic surgery, autologous challenges, and implant complications
0:43
Breast conservation benefits: oncoplastic surgery, autologous challenges, and implant complications
Mariela Vasileva-Slaveva • 4 Oct 2024
ESSO43 highlights: advancements in breast cancer treatment and emphasis on individualized care
2:12
ESSO43 highlights: advancements in breast cancer treatment and emphasis on individualized care
Mariela Vasileva-Slaveva • 4 Oct 2024
Men with breast cancer: biology and diagnosis in Eastern Europe
3:20
Men with breast cancer: biology and diagnosis in Eastern Europe
Mariela Vasileva-Slaveva • 14 May 2021

Related Videos

How will SARMs fit into the current breast cancer treatment paradigm?
1:14
How will SARMs fit into the current breast cancer treatment paradigm?
Rafael Grochot • 2 Jul 2026
Phase I/II trial of vosilasarm and endocrine therapy in AR+/ER+/HER2− breast cancer
1:35
Phase I/II trial of vosilasarm and endocrine therapy in AR+/ER+/HER2− breast cancer
Rafael Grochot • 2 Jul 2026
HYPORT: does the number of fractions of RNRT impact the typical symptoms experienced?
1:07
HYPORT: does the number of fractions of RNRT impact the typical symptoms experienced?
Sanjoy Chatterjee • 17 May 2026
Design and aim of the HYPORT study in regional nodal breast cancer
1:23
Design and aim of the HYPORT study in regional nodal breast cancer
Sanjoy Chatterjee • 17 May 2026
The content of VJOncology is intended for healthcare professionals